Akari Therapeutics (AKTX) Registration filing summary

Company overview and business model

• Focuses on developing next-generation antibody-drug conjugates (ADCs) with proprietary cancer-killing payloads, aiming to improve efficacy and safety over current ADC therapies.

• Lead candidate AKTX-101 targets Trop2 in solid tumors and is in preclinical development, with a Phase 1 trial planned by mid-2027.

• Pipeline includes AKTX-102, a CEACAM5-directed ADC, leveraging the same novel payload platform.

• No commercial products or product revenue to date; business is pre-revenue and dependent on successful R&D and future commercialization.

Financial performance and metrics

• History of operating losses with no assurance of future revenues or profits.

• Requires substantial additional capital to fund ongoing operations and R&D.

• Material weaknesses identified in internal control over financial reporting.

Use of proceeds and capital allocation

• May receive up to $25 million in gross proceeds from sales of ADSs to White Lion Capital under the Purchase Agreement.

• Proceeds, if any, will be used for working capital and general corporate purposes.

• Management has broad discretion over use of funds, which may vary from current intentions.